Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy

May 19 2020

• By Mary Jo Laffler

Digital illustration of lung cancer cells in color background

Related Content

Roche Pushes The Boundaries Of Cancer Immunotherapy

Jun 09 2017

Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals

May 17 2020

Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

May 15 2020

FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review

Feb 19 2020

CASPIAN Proves Too Choppy For AZ Imfinzi/Tremelimumab Combo

Mar 17 2020

Lessons Learned In Immuno-Oncology From Former Roche Exec Dan Chen

Mar 05 2019

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Jul 30 2018

Related Companies

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Genentech, Inc.

AstraZeneca PLC

Additional Topics

Approvals ImmunoOncology Regulation Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window